Lewis Rubin

Title(s)Emeritus Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Is There a Role for Calcium Channel Blockers in the Contemporary Treatment Paradigm for Pulmonary Arterial Hypertension? Circulation. 2024 May 14; 149(20):1565-1567. Rubin LJ. PMID: 38739700.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Sotatercept for pulmonary arterial hypertension: something old and something new. Eur Respir J. 2023 01; 61(1). Rubin LJ, Naeije R. PMID: 36609525.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    3. Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension. Adv Ther. 2022 09; 39(9):4374-4390. Souza R, Delcroix M, Galié N, Jansa P, Mehta S, Pulido T, Rubin L, Sastry BKS, Simonneau G, Sitbon O, Torbicki A, Boyanova N, Chamitava L, Stein C, Channick RN. PMID: 35819570; PMCID: PMC9402744.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Using a knowledge translation program to facilitate guideline- and evidence-based patient management: the PAH-QuERI Extension Program. Pulm Circ. 2022 Jul; 12(3):e12134. McLaughlin VV, Channick RN, Lynum KSB, Oudiz RJ, Selej M, Tapson VF, Rubin LJ. PMID: 36172596; PMCID: PMC9469640.
      View in: PubMed   Mentions:
    5. The physiological basis of pulmonary arterial hypertension. Eur Respir J. 2022 06; 59(6). Naeije R, Richter MJ, Rubin LJ. PMID: 34737219; PMCID: PMC9203839.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    6. It's Time to Put the Term "Pulmonary Vasodilators" to Rest. JACC Basic Transl Sci. 2021 Nov; 6(11):870-871. Rubin LJ. PMID: 34869950; PMCID: PMC8617593.
      View in: PubMed   Mentions: 1  
    7. The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. Eur J Heart Fail. 2022 01; 24(1):205-214. Rosenkranz S, Channick R, Chin KM, Jenner B, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, McLaughlin VV, Du Roure C, Rubin LJ, Sitbon O, Tapson V, Lang IM. PMID: 34806261; PMCID: PMC9298818.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    8. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Adv Ther. 2022 01; 39(1):796-810. Galiè N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, McLaughlin VV, Lassen C, Rubin LJ, Hsu Schmitz SF, Sitbon O, Tapson VF, Chin KM. PMID: 34727317; PMCID: PMC8799580.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    9. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. Chest. 2021 07; 160(1):277-286. Gaine S, Sitbon O, Channick RN, Chin KM, Sauter R, Galiè N, Hoeper MM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson V, Ghofrani HA, Lang I. PMID: 33545163.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    10. Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects. Vascul Pharmacol. 2021 06; 138:106840. Roscigno RF, Vaughn T, Parsley E, Hunt T, Eldon MA, Rubin LJ. PMID: 33545364.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    11. Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1): Multicenter, Early Feasibility Study. JACC Cardiovasc Interv. 2020 04 27; 13(8):989-999. Rothman AMK, Vachiery JL, Howard LS, Mikhail GW, Lang IM, Jonas M, Kiely DG, Shav D, Shabtay O, Avriel A, Lewis GD, Rosenzweig EB, Kirtane AJ, Kim NH, Mahmud E, McLaughlain VV, Chetcuti S, Leon MB, Ben-Yehuda O, Rubin LJ. PMID: 32327095.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    12. Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. J Heart Lung Transplant. 2020 04; 39(4):300-309. Sitbon O, Chin KM, Channick RN, Benza RL, Di Scala L, Gaine S, Ghofrani HA, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson VF, Galiè N, Hoeper MM. PMID: 32061506.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    13. Pulmonary artery denervation using catheter-based ultrasonic energy. EuroIntervention. 2019 Oct 20; 15(8):722-730. Rothman A, Jonas M, Castel D, Tzafriri AR, Traxler H, Shav D, Leon MB, Ben-Yehuda O, Rubin L. PMID: 31062694.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    14. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019 10; 54(4). Torres F, Farber H, Ristic A, McLaughlin V, Adams J, Zhang J, Klassen P, Shanahan W, Grundy J, Hoffmann I, Cabell C, Escribano Subías P, Sood N, Keogh A, D'Souza G, Rubin L. PMID: 31391223.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    15. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. J Heart Lung Transplant. 2019 12; 38(12):1286-1295. McLaughlin VV, Vachiery JL, Oudiz RJ, Rosenkranz S, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rubin LJ, Blair C, Langley J, Hoeper MM, AMBITION Study Group. PMID: 31648845.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    16. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation. 2019 05 21; 139(21):2440-2450. Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF. PMID: 30982349; PMCID: PMC6530970.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    17. Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circ Cardiovasc Qual Outcomes. 2019 05; 12(5):e005095. Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani HA, Hennessy B, Jansa P, Mehta S, Perchenet L, Pulido T, Rosenberg D, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Wei LJ, Channick R, Benza R. PMID: 31109190; PMCID: PMC7665498.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    18. An insider view on the World Symposium on Pulmonary Hypertension. Lancet Respir Med. 2019 06; 7(6):484-485. Humbert M, Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. PMID: 30956061.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    19. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J. 2019 01; 53(1). Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, Zamanian RT, Rubin LJ. PMID: 30545975; PMCID: PMC6351342.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansAnimals
    20. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019 01; 53(1). Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. PMID: 30552088; PMCID: PMC6351332.
      View in: PubMed   Mentions: 168     Fields:    Translation:Humans
    21. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. Eur J Heart Fail. 2019 03; 21(3):352-359. Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N. PMID: 30632656; PMCID: PMC6607487.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    22. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial. J Heart Lung Transplant. 2019 02; 38(2):194-202. Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ, AMBITION Study Group. PMID: 30522722.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    23. Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score. J Heart Lung Transplant. 2018 12; 37(12):1410-1417. Frost AE, Hoeper MM, Barberá JA, Vachiery JL, Blair C, Langley J, Rubin LJ. PMID: 30209017.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    24. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS One. 2018; 13(3):e0193226. Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G. PMID: 29590122; PMCID: PMC5873992.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    25. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. J Am Coll Cardiol. 2018 02 20; 71(7):752-763. McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N. PMID: 29447737.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    26. Assessing Prognosis of Pulmonary Arterial Hypertension in the Therapeutic Era: Importance of Serial Hemodynamic Measurements. Circulation. 2018 02 13; 137(7):705-706. Rubin LJ. PMID: 29440197.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. 2018 02; 51(2). Vachiéry JL, Delcroix M, Al-Hiti H, Efficace M, Hutyra M, Lack G, Papadakis K, Rubin LJ. PMID: 29437943.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    28. Cor Pulmonale Revisited. From Ferrer and Harvey to the Present. Ann Am Thorac Soc. 2018 02; 15(Suppl 1):S42-S44. Rubin LJ. PMID: 29461887.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    29. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Am J Cardiovasc Drugs. 2018 Feb; 18(1):37-47. Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S. PMID: 29307087; PMCID: PMC5772136.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCellsCTClinical Trials
    30. Overdue to understand anticoagulation in pulmonary arterial hypertension. Pulm Circ. 2018 Jan-Mar; 8(1):2045893217743184. Parikh KS, Gray MP, Rubin LJ, Badesch D, Krasuski RA. PMID: 29534640; PMCID: PMC5858629.
      View in: PubMed   Mentions: 1  
    31. Update on pulmonary arterial hypertension research: proceedings from a meeting of experts. Curr Med Res Opin. 2018 02; 34(2):263-273. McLaughlin V, Bacchetta M, Badesch D, Benza R, Burger C, Chin K, Frantz R, Frost A, Hemnes A, Kim NH, Rosenzweig EB, Rubin L. PMID: 29132217.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    32. Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice. Eur Respir Rev. 2017 Dec 31; 26(146). Chan SY, Rubin LJ. PMID: 29263174; PMCID: PMC5842433.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    33. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. J Heart Lung Transplant. 2018 03; 37(3):401-408. Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ. PMID: 29096938.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    34. Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension. Eur Respir J. 2017 09; 50(3). Rubin LJ. PMID: 28893872.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017 08; 50(2). Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Hoeper MM. PMID: 28818881; PMCID: PMC5593379.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    36. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017 04 14; 38(15):1147-1155. Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, Le Brun FO, Mehta S, Perchenet L, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. PMID: 28329315; PMCID: PMC5400052.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    37. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017 Jul; 76(7):1219-1227. Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ, AMBITION investigators. PMID: 28039187; PMCID: PMC5530350.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    38. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. J Heart Lung Transplant. 2017 May; 36(5):509-519. Galiè N, Grimminger F, Grünig E, Hoeper MM, Humbert M, Jing ZC, Keogh AM, Langleben D, Rubin LJ, Fritsch A, Davie N, Ghofrani HA. PMID: 28190787.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    39. Future perspectives in pulmonary arterial hypertension. Eur Respir Rev. 2016 Dec; 25(142):381-389. Simonneau G, Hoeper MM, McLaughlin V, Rubin L, Galiè N. PMID: 27903660; PMCID: PMC9487553.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    40. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med. 2016 11; 4(11):894-901. Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JHN, Blair C, Rubin LJ, Vachiery JL. PMID: 27745818.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    41. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. Chest. 2017 Jan; 151(1):106-118. Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. PMID: 27671974.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    42. The adrenergic nervous system as a therapeutic target in pulmonary arterial hypertension: a cautionary tale. Eur Respir J. 2016 09; 48(3):617-8. Rubin LJ. PMID: 27581405.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    43. Pulmonary Hypertension Overlap Syndromes: A Real Entity? J Am Coll Cardiol. 2016 07 26; 68(4):379-81. Ben-Yehuda O, Rubin LJ. PMID: 27443434.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    44. Are Animal Models of Pulmonary Hypertension Relevant to the Clinical Disease? J Am Coll Cardiol. 2016 05 03; 67(17):2047-9. Rubin LJ. PMID: 27126532.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    45. Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial. Chest. 2016 Jul; 150(1):27-34. Bourge RC, Waxman AB, Gomberg-Maitland M, Shapiro SM, Tarver JH, Zwicke DL, Feldman JP, Chakinala MM, Frantz RP, Torres F, Cerkvenik J, Morris M, Thalin M, Peterson L, Rubin LJ. PMID: 27396777.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    46. Pulmonary Artery Denervation for Pulmonary Artery Hypertension. JACC Cardiovasc Interv. 2015 Dec 28; 8(15):2024-2025. Rubin LJ. PMID: 26738674.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    47. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24; 373(26):2522-33. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV, GRIPHON Investigators. PMID: 26699168.
      View in: PubMed   Mentions: 347     Fields:    Translation:HumansCTClinical Trials
    48. Improving patient outcomes in pulmonary hypertension. Eur Respir Rev. 2015 Dec; 24(138):550-1. Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. PMID: 26621969; PMCID: PMC9487624.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    49. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J. 2015 Dec; 46(6):1711-20. Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BK, Sitbon O, Souza R, Torbicki A, Rubin LJ. PMID: 26493786; PMCID: PMC4664609.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    50. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27; 373(9):834-44. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ, AMBITION Investigators. PMID: 26308684.
      View in: PubMed   Mentions: 402     Fields:    Translation:Humans
    51. Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning. Eur Respir J. 2015 Aug; 46(2):297-8. Vachiery JL, Rubin LJ. PMID: 26232474.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    52. The beta-adrenergic receptor in pulmonary arterial hypertension: a novel therapeutic target? J Am Coll Cardiol. 2015 Feb 24; 65(7):681-3. Rubin LJ. PMID: 25677429.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    53. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015 May; 45(5):1303-13. Rubin LJ, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh A, Langleben D, Fritsch A, Menezes F, Davie N, Ghofrani HA. PMID: 25614164.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    54. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study. J Heart Lung Transplant. 2015 Mar; 34(3):338-47. Langleben D, Galiè N, He J, Huang Y, Humbert M, Keogh A, Rubin LJ, Zhou D, Curram J, Davie N, Ghofrani HA. PMID: 25703961.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    55. New horizons in pulmonary arterial hypertension management. Eur Respir Rev. 2014 Dec; 23(134):408-9. McLaughlin V, Simonneau G, Galiè N, Rubin LJ. PMID: 25445938; PMCID: PMC9487407.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    56. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015 Jan; 3(1):1-8. Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO, Mehta S, Pulido T, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Galiè N. PMID: 25457902.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    57. [New trial designs and potential therapies for pulmonary artery hypertension]. Turk Kardiyol Dern Ars. 2014 Oct; 42 Suppl 1:106-18. Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin LJ. PMID: 25697038.
      View in: PubMed   Mentions:    Fields:    
    58. [Updated treatment algorithm of pulmonary arterial hypertension]. Turk Kardiyol Dern Ars. 2014 Oct; 42 Suppl 1:78-94. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A. PMID: 25697036.
      View in: PubMed   Mentions: 2     Fields:    
    59. Chronic thromboembolic pulmonary hypertension. Lancet Respir Med. 2014 Jul; 2(7):573-82. Hoeper MM, Madani MM, Nakanishi N, Meyer B, Cebotari S, Rubin LJ. PMID: 24898750.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    60. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014 07; 33(7):689-97. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar M, Layton GR, Sitbon O, Badesch DB, PACES Study Group. PMID: 24815795.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    61. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol. 2014 Mar 15; 172(2):332-9. Simonneau G, Galiè N, Jansa P, Meyer GM, Al-Hiti H, Kusic-Pajic A, Lemarié JC, Hoeper MM, Rubin LJ. PMID: 24525158.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    62. Macitentan and pulmonary arterial hypertension. N Engl J Med. 2014 01 02; 370(1):82-3. Pulido T, Rubin LJ, Simonneau G. PMID: 24382071.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    63. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013 Dec 24; 62(25 Suppl):D60-72. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A. PMID: 24355643.
      View in: PubMed   Mentions: 234     Fields:    Translation:HumansAnimals
    64. New trial designs and potential therapies for pulmonary artery hypertension. J Am Coll Cardiol. 2013 Dec 24; 62(25 Suppl):D82-91. Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin LJ. PMID: 24355645; PMCID: PMC4117578.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimals
    65. Riociguat for pulmonary hypertension. N Engl J Med. 2013 12 05; 369(23):2268. Ghofrani HA, Simonneau G, Rubin LJ, Authors of CHEST-1 and PATENT-1. PMID: 24304056.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    66. A paradigm shift in pulmonary arterial hypertension management. Eur Respir Rev. 2013 Dec; 22(130):423-6. Rubin LJ, Galiè N, Simonneau G, McLaughlin V. PMID: 24293459; PMCID: PMC9639191.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    67. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf. 2014 Mar; 13(3):391-405. Dingemanse J, Sidharta PN, Maddrey WC, Rubin LJ, Mickail H. PMID: 24261583.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    68. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. Am Heart J. 2014 Feb; 167(2):218-225.e1. Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V. PMID: 24439983.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    69. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013 Sep; 144(3):952-958. Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, Kotlyar E, McSwain CS, Laliberte K, Arneson C, Rubin LJ, FREEDOM-C2 Study Team. PMID: 23669822.
      View in: PubMed   Mentions: 108     Fields:    Translation:Humans
    70. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29; 369(9):809-18. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G, SERAPHIN Investigators. PMID: 23984728.
      View in: PubMed   Mentions: 451     Fields:    Translation:HumansCTClinical Trials
    71. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013 Jul 25; 369(4):330-40. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ, PATENT-1 Study Group. PMID: 23883378.
      View in: PubMed   Mentions: 475     Fields:    Translation:HumansCTClinical Trials
    72. Cor pulmonale revisited. J Am Coll Cardiol. 2013 Sep 17; 62(12):1112-1113. Rubin LJ. PMID: 23850928.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    73. Robyn J. Barst, MD. Eur Respir J. 2013 Jul; 42(1):16-7. Rubin LJ. PMID: 23971081.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    74. Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT. Circulation. 2013 Jul 30; 128(5):475-6. Rubin LJ. PMID: 23775259.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    75. Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap. Chest. 2013 Feb 01; 143(2):324-332. McLaughlin VV, Langer A, Tan M, Clements PJ, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Pulmonary Arterial Hypertension-Quality Enhancement Research Initiative (PAH-QuERI) Investigators. PMID: 22910999.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    76. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. Cardiovasc Ther. 2013 Feb; 31(1):38-44. Bourge RC, Tapson VF, Safdar Z, Benza RL, Channick RN, Rosenzweig EB, Shapiro S, White RJ, McSwain CS, Gotzkowsky SK, Nelsen AC, Rubin LJ. PMID: 22970909; PMCID: PMC3561685.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    77. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013 Feb 05; 127(5):624-33. Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Laliberte K, Arneson C, Rubin LJ. PMID: 23307827.
      View in: PubMed   Mentions: 119     Fields:    Translation:Humans
    78. Treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2013 Jan; 11(1):13-25. Torres F, Rubin LJ. PMID: 23259441.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    79. Pulmonary hypertension: current management and future directions. Handb Exp Pharmacol. 2013; 218:551-5. Rubin LJ. PMID: 24092355.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    80. Pulmonary arterial hypertension: bridging the present to the future. Eur Respir Rev. 2012 Dec 01; 21(126):267-70. Humbert M, Souza R, Galiè N, McLaughlin V, Simonneau G, Rubin L. PMID: 23204116; PMCID: PMC9487232.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    81. Developing a heart score: next steps. Am J Cardiol. 2012 Sep 15; 110(6 Suppl):49S-51S. Galiè N, Rubin L, Simonneau G. PMID: 22921032.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    82. The 6-minute walk test in pulmonary arterial hypertension: how far is enough? Am J Respir Crit Care Med. 2012 Sep 01; 186(5):396-7. Rubin LJ. PMID: 22942342.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    83. The study of risk in pulmonary arterial hypertension. Eur Respir Rev. 2012 Sep 01; 21(125):234-8. Rubin LJ, Simonneau G, Badesch D, Galiè N, Humbert M, Keogh A, Massaro J, Matucci Cerinic M, Sitbon O, Kymes S. PMID: 22941888; PMCID: PMC9487334.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    84. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci. 2012 Oct 15; 91(13-14):528-39. Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, Barton M. PMID: 22967485.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimals
    85. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. Expert Opin Drug Saf. 2012 Nov; 11(6):1003-11. Vizza CD, Fedele F, Pezzuto B, Rubin LJ. PMID: 22861496.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    86. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci. 2012 Oct 15; 91(13-14):517-21. Rubin LJ. PMID: 22884806.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    87. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol. 2012 Nov 15; 110(10):1546-50. de Jesus Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, Jain M, Bourge RC, Kudelko K, Spiekerkoetter E, Liu J, Hsi A, Zamanian RT. PMID: 22853986.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    88. Exercise training for pulmonary hypertension: another prescription to write? Eur Respir J. 2012 Jul; 40(1):7-8. Rubin LJ. PMID: 22753832.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    89. Inhaled treprostinil: a therapeutic review. Drug Des Devel Ther. 2012; 6:19-28. Channick RN, Voswinckel R, Rubin LJ. PMID: 22291467; PMCID: PMC3267519.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    90. Combination therapy for pulmonary artery hypertension: what is the evidence? Cardiology. 2011; 120(3):172-3. Rubin LJ. PMID: 22248863.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    91. A decade of achievement in pulmonary hypertension. Eur Respir Rev. 2011 Dec; 20(122):215-7. Humbert M, Simonneau G, Rubin LJ. PMID: 22130812; PMCID: PMC9487738.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    92. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant. 2011 Dec; 30(12):1327-33. Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubin LJ. PMID: 22055098.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    93. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum. 2012 Apr; 64(4):1257-62. Kovacs G, Maier R, Aberer E, Brodmann M, Graninger W, Kqiku X, Scheidl S, Tröster N, Hesse C, Rubin L, Olschewski H. PMID: 22127844.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    94. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis. 2012 Feb; 71(2):249-52. Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A, Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators. PMID: 21998119.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    95. Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol. 2011 Nov; 38(11):2419-27. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O, Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis. PMID: 21965635.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    96. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther. 2012 Apr; 30(2):93-9. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ, ARIES-3 Study Group. PMID: 21884013.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    97. Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Res Ther. 2011 Jun 20; 13(3):114. Denton CP, Avouac J, Behrens F, Furst DE, Foeldvari I, Humbert M, Huscher D, Kowal-Bielecka O, Matucci-Cerinic M, Nash P, Opitz CF, Pittrow D, Rubin LJ, Seibold JR, Distler O. PMID: 21699746; PMCID: PMC3218892.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    98. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011 Nov; 140(5):1274-1283. Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ, SUPER-2 Study Group. PMID: 21546436.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    99. New frontiers in pulmonary hypertension. Expert Rev Respir Med. 2011 Apr; 5(2):139-40. Rubin LJ, Morrell NW. PMID: 21510723.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    100. Metabolic dysfunction in the pathogenesis of pulmonary hypertension. Cell Metab. 2010 Oct 06; 12(4):313-314. Rubin LJ. PMID: 20889122.
      View in: PubMed   Mentions: 5     Fields:    
    101. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 2010 Jul; 62(7):2101-8. Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, Matucci Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Black CM. PMID: 20506355.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    102. Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Clin Exp Rheumatol. 2010 Mar-Apr; 28(2 Suppl 58):S47-52. Huscher D, Pittrow D, Distler O, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Kowal-Bielecka O, Avouac J, Behrens F, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, EPOSS-OMERACT Group. PMID: 20576214.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    103. Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest. 2010 Jun; 137(6 Suppl):85S-94S. Elliott CG, Barst RJ, Seeger W, Porres-Aguilar M, Brown LM, Zamanian RT, Rubin LJ. PMID: 20522584.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    104. Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis. 2010 Jul; 69(7):1360-3. Avouac J, Kowal-Bielecka O, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Distler O, Furst DE, EPOSS Group. PMID: 20472586.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    105. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010 May 04; 55(18):1915-22. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. PMID: 20430262.
      View in: PubMed   Mentions: 182     Fields:    Translation:Humans
    106. Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Curr Opin Pulm Med. 2010 May; 16 Suppl 1:S11-9. Galiè N, Simonneau G, Barst RJ, Badesch D, Rubin L. PMID: 20375660.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    107. Perspective on the optimal endpoints for pulmonary arterial hypertension trials. Curr Opin Pulm Med. 2010 May; 16 Suppl 1:S43-6. Rubin L, Simonneau G. PMID: 20375664.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    108. Editor's response to "ethical issues associated with globalization of placebo-controlled trials in pulmonary arterial hypertension". J Heart Lung Transplant. 2010 Jul; 29(7):827-8. Park MH, Rubin LJ. PMID: 20417131.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    109. Echocardiographic assessment of hemodynamic changes produced by two methods of inducing fluid deficit in dogs. J Vet Intern Med. 2010 Mar-Apr; 24(2):348-53. Fine DM, Durham HE, Rossi NF, Spier AW, Selting K, Rubin LJ. PMID: 20051004.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    110. Phosphodiesterase inhibitors for pulmonary hypertension. N Engl J Med. 2010 Feb 11; 362(6):559-60; author reply 560. Galiè N, Rubin LJ, Simonneau G. PMID: 20175298.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    111. The globalization of clinical trials in pulmonary arterial hypertension. J Heart Lung Transplant. 2010 Feb; 29(2):157-8. Park MH, Rubin LJ. PMID: 20113908.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    112. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol. 2010 Jan; 37(1):105-15. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O, EPOSS Group. PMID: 19955042.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    113. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Nov 17; 54(21):1971-81. Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ, ARIES Study Group. PMID: 19909879.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    114. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol. 2009 Oct; 36(10):2356-61. Khanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, Foeldvari I, Giannini E, Huscher D, Kowal-Bielecka O, Lovell D, Matucci-Cerinic M, Mayes M, Merkel PA, Nash P, Opitz CF, Pittrow D, Rubin L, Seibold JR, Steen V, Strand CV, Tugwell PS, Varga J, Zink A, Furst DE, CRISS, EPOSS. PMID: 19820225.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    115. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009 Dec; 34(6):1219-63. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (, European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT), Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. PMID: 19749199.
      View in: PubMed   Mentions: 345     Fields:    Translation:Humans
    116. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009 Oct; 36(10):2244-9. Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, Kral KM, Raphiou IH, Crater GD. PMID: 19723905.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    117. Combining evidence and experience in pulmonary hypertension. Eur Respir Rev. 2009 Sep; 18(113):135-6. Humbert M, Rubin LJ. PMID: 20956133.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 Oct; 30(20):2493-537. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, ESC Committee for Practice Guidelines (CPG). PMID: 19713419.
      View in: PubMed   Mentions: 955     Fields:    Translation:Humans
    119. Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med. 2009 Nov 01; 180(9):881-6. Kovacs G, Maier R, Aberer E, Brodmann M, Scheidl S, Tröster N, Hesse C, Salmhofer W, Graninger W, Gruenig E, Rubin LJ, Olschewski H. PMID: 19679693.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    120. Medical treatment of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2009 Aug; 30(4):484-92. Adamali H, Gaine SP, Rubin LJ. PMID: 19634087.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    121. End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Eur Respir J. 2009 Jul; 34(1):231-42. Peacock AJ, Naeije R, Galiè N, Rubin L. PMID: 19567606.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    122. Future perspectives for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30; 54(1 Suppl):S108-S117. Ghofrani HA, Barst RJ, Benza RL, Champion HC, Fagan KA, Grimminger F, Humbert M, Simonneau G, Stewart DJ, Ventura C, Rubin LJ. PMID: 19555854; PMCID: PMC4883573.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    123. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30; 54(1 Suppl):S78-S84. Barst RJ, Gibbs JSR, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galiè N. PMID: 19555861; PMCID: PMC3686287.
      View in: PubMed   Mentions: 149     Fields:    Translation:Humans
    124. Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer? Eur Respir J. 2009 Jun; 33(6):1247-9. Opitz CF, Rubin LJ. PMID: 19483043.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    125. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr 28; 53(17):1573-619. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, American College of Cardiology Foundation Task Force on Expert Consensus Documents, American Heart Association, American College of Chest Physicians, American Thoracic Society, Inc, Pulmonary Hypertension Association. PMID: 19389575.
      View in: PubMed   Mentions: 542     Fields:    Translation:HumansPHPublic Health
    126. A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation. 2009 May 05; 119(17):2313-22. Yu Y, Keller SH, Remillard CV, Safrina O, Nicholson A, Zhang SL, Jiang W, Vangala N, Landsberg JW, Wang JY, Thistlethwaite PA, Channick RN, Robbins IM, Loyd JE, Ghofrani HA, Grimminger F, Schermuly RT, Cahalan MD, Rubin LJ, Yuan JX. PMID: 19380626; PMCID: PMC2749566.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCells
    127. Endothelin and the systemic circulation a therapeutic target worth revisiting? J Am Coll Cardiol. 2009 Apr 14; 53(15):1318-9. Rubin LJ. PMID: 19358947.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    128. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009 Apr 28; 119(16):2250-94. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ, ACCF/AHA. PMID: 19332472.
      View in: PubMed   Mentions: 355     Fields:    Translation:Humans
    129. Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009 Jun; 296(6):L870-8. Yao W, Firth AL, Sacks RS, Ogawa A, Auger WR, Fedullo PF, Madani MM, Lin GY, Sakakibara N, Thistlethwaite PA, Jamieson SW, Rubin LJ, Yuan JX. PMID: 19286928; PMCID: PMC2692803.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    130. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008 Dec 16; 52(25):2127-34. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ, Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group. PMID: 19095129.
      View in: PubMed   Mentions: 142     Fields:    Translation:HumansCTClinical Trials
    131. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther. 2009 Feb; 22(1):50-6. Voswinckel R, Reichenberger F, Gall H, Schmehl T, Gessler T, Schermuly RT, Grimminger F, Rubin LJ, Seeger W, Ghofrani HA, Olschewski H. PMID: 19071225.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    132. Exercise-induced pulmonary arterial hypertension: a new addition to the spectrum of pulmonary vascular diseases. Circulation. 2008 Nov 18; 118(21):2120-1. Oudiz RJ, Rubin LJ. PMID: 19015412.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    133. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008 Oct 21; 149(8):521-30. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB, PACES Study Group. PMID: 18936500.
      View in: PubMed   Mentions: 186     Fields:    Translation:Humans
    134. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009 Jan; 135(1):122-129. McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ. PMID: 18812445.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    135. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest. 2009 Jan; 135(1):130-136. Chin KM, Channick RN, de Lemos JA, Kim NH, Torres F, Rubin LJ. PMID: 18719056.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    136. Prednisolone inhibits PDGF-induced nuclear translocation of NF-kappaB in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2008 Oct; 295(4):L648-57. Ogawa A, Firth AL, Yao W, Rubin LJ, Yuan JX. PMID: 18708631; PMCID: PMC2575943.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    137. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest. 2008 Oct; 134(4):775-782. Benza RL, Barst RJ, Galie N, Frost A, Girgis RE, Highland KB, Strange C, Black CM, Badesch DB, Rubin L, Fleming TR, Naeije R. PMID: 18625676.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    138. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther. 2008 Oct; 21(5):824-32. Voswinckel R, Reichenberger F, Enke B, Kreckel A, Krick S, Gall H, Schermuly RT, Grimminger F, Rubin LJ, Olschewski H, Seeger W, Ghofrani HA. PMID: 18657627.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    139. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum. 2008 Jun 15; 59(6):867-75. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE, EPOSS-Omeract Group. PMID: 18512721.
      View in: PubMed   Mentions: 22     Fields:    
    140. BMPR2 mutation and outcome in pulmonary arterial hypertension: clinical relevance to physicians and patients. Am J Respir Crit Care Med. 2008 Jun 15; 177(12):1300-1. Rubin LJ. PMID: 18522952.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    141. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 Jun 10; 117(23):3010-9. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multic. PMID: 18506008.
      View in: PubMed   Mentions: 330     Fields:    Translation:Humans
    142. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008 Apr 22; 51(16):1527-38. Chin KM, Rubin LJ. PMID: 18420094.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    143. Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future. Rheum Dis Clin North Am. 2008 Feb; 34(1):191-7; viii. Rubin LJ. PMID: 18329540.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    144. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007 Dec; 34(12):2417-22. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N, Simonneau G, SUPER Study Group. PMID: 17985403.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCTClinical Trials
    145. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels. Chest. 2007 Sep; 132(3):786-92. Chin KM, Channick RN, Kim NH, Rubin LJ. PMID: 17646224.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    146. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007 Jun; 131(6):1917-28. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. PMID: 17565025.
      View in: PubMed   Mentions: 122     Fields:    Translation:Humans
    147. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med. 2007 Jun 15; 175(12):1272-9. Anthi A, Machado RF, Jison ML, Taveira-Dasilva AM, Rubin LJ, Hunter L, Hunter CJ, Coles W, Nichols J, Avila NA, Sachdev V, Chen CC, Gladwin MT. PMID: 17379852; PMCID: PMC2176091.
      View in: PubMed   Mentions: 89     Fields:    Translation:Humans
    148. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol. 2007 May; 292(5):C1837-53. Remillard CV, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, Conger D, Nicholson A, Rana BK, Channick RN, Rubin LJ, O'connor DT, Yuan JX. PMID: 17267549.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansAnimalsCells
    149. Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease. Arthritis Res Ther. 2007; 9 Suppl 2:S10. Rubin LJ, Black CM, Denton CP, Seibold JR. PMID: 17767739; PMCID: PMC2072884.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    150. Upregulation of Na+/Ca2+ exchanger contributes to the enhanced Ca2+ entry in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol. 2007 Jun; 292(6):C2297-305. Zhang S, Dong H, Rubin LJ, Yuan JX. PMID: 17192285.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    151. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006 Dec; 130(6):1657-63. Chin KM, Channick RN, Rubin LJ. PMID: 17166979.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    152. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006 Dec 19; 48(12):2546-52. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, Barst RJ, Ghofrani HA, Jing ZC, Opitz C, Seyfarth HJ, Halank M, McLaughlin V, Oudiz RJ, Ewert R, Wilkens H, Kluge S, Bremer HC, Baroke E, Rubin LJ. PMID: 17174196.
      View in: PubMed   Mentions: 156     Fields:    Translation:Humans
    153. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006 Oct 24; 114(17):1883-91. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB, National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Righ. PMID: 17060398.
      View in: PubMed   Mentions: 409     Fields:    Translation:HumansCells
    154. Endothelin-1 and the pulmonary vascular response to altitude: a new therapeutic target? Circulation. 2006 Sep 26; 114(13):1350-1. Rubin LJ. PMID: 17000920.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    155. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol. 2006 Oct 17; 48(8):1672-81. Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S, Gall H, Gessler T, Schmehl T, Ghofrani HA, Schermuly RT, Grimminger F, Rubin LJ, Seeger W, Olschewski H. PMID: 17045906.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    156. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006 Oct 03; 48(7):1433-7. Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. PMID: 17010807.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    157. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J. 2006 Sep; 152(3):521-6. Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, McLaughlin V, Murali S, Oudiz RJ, Robbins IM, Tapson V, Abenhaim L, Constantine G. PMID: 16923424.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    158. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006 Sep; 3(7):608-14. Peacock A, Simonneau G, Rubin L. PMID: 16963542.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    159. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc. 2006 Sep; 3(7):601-7. Rubin LJ, Hoeper MM, Klepetko W, Galiè N, Lang IM, Simonneau G. PMID: 16963541.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    160. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006 Dec 01; 174(11):1257-63. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. PMID: 16946127.
      View in: PubMed   Mentions: 146     Fields:    Translation:Humans
    161. Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Rheumatology (Oxford). 2006 Dec; 45(12):1455-7. Distler O, Behrens F, Huscher D, Foeldvari I, Zink A, Nash P, Denton CP, Humbert M, Matucci-Cerinic M, Seibold J, Rubin L, Furst DE. PMID: 16920751.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    162. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006 Dec; 28(6):1195-203. Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, Rubin LJ. PMID: 16899485.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans
    163. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis. 2007 Feb; 66(2):169-73. Buch MH, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells AU, Matucci-Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Black CM, Seibold JR. PMID: 16868020; PMCID: PMC1798506.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    164. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006 Oct; 65(10):1336-40. Denton CP, Humbert M, Rubin L, Black CM. PMID: 16793845; PMCID: PMC1798307.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    165. Chronic thromboembolic pulmonary hypertension. Circulation. 2006 Apr 25; 113(16):2011-20. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. PMID: 16636189.
      View in: PubMed   Mentions: 125     Fields:    Translation:Humans
    166. Update in pulmonary hypertension 2005. Am J Respir Crit Care Med. 2006 Mar 01; 173(5):499-505. Hoeper MM, Rubin LJ. PMID: 16493163.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    167. Pulmonary arterial hypertension. Proc Am Thorac Soc. 2006; 3(1):111-5. Rubin LJ. PMID: 16493158.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    168. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 Nov 17; 353(20):2148-57. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G, Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. PMID: 16291984.
      View in: PubMed   Mentions: 632     Fields:    Translation:Humans
    169. Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. Thorax. 2006 Jan; 61(1):80-5. de Jong PA, Lindblad A, Rubin L, Hop WC, de Jongste JC, Brink M, Tiddens HA. PMID: 16244089; PMCID: PMC2080716.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    170. Successful liver transplantation in a child with severe portopulmonary hypertension treated with epoprostenol. J Pediatr Gastroenterol Nutr. 2005 Oct; 41(4):466-8. Laving A, Khanna A, Rubin L, Ing F, Dohil R, Lavine JE. PMID: 16205516.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    171. Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2005 Sep; 6(11):1921-30. Hsu HH, Rubin LJ. PMID: 16144511.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    172. Management following pulmonary thromboendarterectomy: experience versus evidence. Crit Care Med. 2005 Sep; 33(9):2132-3. Kim NH, Rubin LJ. PMID: 16148499.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    173. Current treatment strategies for pulmonary arterial hypertension. J Intern Med. 2005 Sep; 258(3):199-215. Lee SH, Rubin LJ. PMID: 16115293.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    174. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med. 2005 Aug 16; 143(4):282-92. Rubin LJ, Badesch DB. PMID: 16103472.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    175. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005 Aug 02; 46(3):529-35. Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ. PMID: 16053970.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansCTClinical Trials
    176. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005 Dec; 60(12):1025-30. Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, Humbert M, Rainisio M, Rubin LJ, Simonneau G. PMID: 16055621; PMCID: PMC1747276.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    177. Ambrisentan for pulmonary arterial hypertension. Future Cardiol. 2005 Jul; 1(4):425-32. Rubin LJ, Dufton C, Gerber MJ. PMID: 19804142.
      View in: PubMed   Mentions: 7     Fields:    
    178. [Guidelines on diagnosis and treatment of pulmonary arterial hypertension]. Rev Esp Cardiol. 2005 May; 58(5):523-66. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Grupo de Trabajo sobre el diagnóstico y tratamiento de la Hipertensión Arterial Pulmonar de la Socie. PMID: 15899198.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    179. Epoprostenol and nesiritide in pulmonary hypertension. Chest. 2005 May; 127(5):1870. Rubin LJ. PMID: 15888882.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    180. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation. 2005 Feb 08; 111(5):534-8. Yuan JX, Rubin LJ. PMID: 15699271.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
    181. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005 Feb; 25(2):244-9. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, Rainisio M, Simonneau G, Rubin LJ. PMID: 15684287.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansCTClinical Trials
    182. The right ventricle in pulmonary hypertension. Coron Artery Dis. 2005 Feb; 16(1):13-8. Chin KM, Kim NH, Rubin LJ. PMID: 15654194.
      View in: PubMed   Mentions: 128     Fields:    Translation:Humans
    183. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004 Dec; 25(24):2243-78. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J, Task Force. PMID: 15589643.
      View in: PubMed   Mentions: 204     Fields:    Translation:Humans
    184. Metabolic activation of AMP kinase in vascular smooth muscle. J Appl Physiol (1985). 2005 Jan; 98(1):296-306. Rubin LJ, Magliola L, Feng X, Jones AW, Hale CC. PMID: 15377643.
      View in: PubMed   Mentions: 39     Fields:    Translation:AnimalsCells
    185. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2004 Sep 21; 101(38):13861-6. Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, Platoshyn O, Tigno DD, Thistlethwaite PA, Rubin LJ, Yuan JX. PMID: 15358862; PMCID: PMC518765.
      View in: PubMed   Mentions: 193     Fields:    Translation:HumansCells
    186. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res. 2004 Sep; 68(2):75-103. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX. PMID: 15313118.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansAnimalsCells
    187. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004 Sep; 24(3):353-9. Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G. PMID: 15358690.
      View in: PubMed   Mentions: 134     Fields:    Translation:HumansCTClinical Trials
    188. Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes. Am J Respir Crit Care Med. 2004 Nov 15; 170(10):1101-7. Kunichika N, Landsberg JW, Yu Y, Kunichika H, Thistlethwaite PA, Rubin LJ, Yuan JX. PMID: 15317671.
      View in: PubMed   Mentions: 40     Fields:    Translation:AnimalsCells
    189. Sildenafil for enhanced performance at high altitude? Ann Intern Med. 2004 Aug 03; 141(3):233-5. Rubin LJ, Naeije R. PMID: 15289224.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    190. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004 Aug; 126(2):420-7. Oudiz RJ, Schilz RJ, Barst RJ, Galié N, Rich S, Rubin LJ, Simonneau G, Treprostinil Study Group. PMID: 15302727.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCTClinical Trials
    191. Endogenous testosterone increases L-type Ca2+ channel expression in porcine coronary smooth muscle. Am J Physiol Heart Circ Physiol. 2004 Nov; 287(5):H2091-8. Bowles DK, Maddali KK, Ganjam VK, Rubin LJ, Tharp DL, Turk JR, Heaps CL. PMID: 15242831.
      View in: PubMed   Mentions: 20     Fields:    Translation:Animals
    192. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul; 126(1 Suppl):4S-6S. Rubin LJ, American College of Chest Physicians. PMID: 15249490.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    193. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul; 126(1 Suppl):7S-10S. Rubin LJ, American College of Chest Physicians. PMID: 15249491.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    194. Mars or venus--is sex a risk factor for recurrent venous thromboembolism? N Engl J Med. 2004 Jun 17; 350(25):2614-6. Elliott CG, Rubin LJ. PMID: 15201419.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    195. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):81S-88S. Galiè N, Seeger W, Naeije R, Simonneau G, Rubin LJ. PMID: 15194183.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    196. Pulmonary arterial hypertension: a look to the future. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):89S-90S. Rubin LJ, Galiè N. PMID: 15194184.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    197. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):62S-67S. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. PMID: 15194180.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    198. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):5S-12S. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. PMID: 15194173.
      View in: PubMed   Mentions: 347     Fields:    Translation:Humans
    199. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004 Apr; 23(4):595-600. Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, Jamieson SW, Rubin LJ. PMID: 15083760.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    200. High-fat diet alters K+-currents in porcine coronary arteries and adenosine sensitivity during metabolic inhibition. J Cardiovasc Pharmacol. 2004 Apr; 43(4):495-503. Franke R, Yang Y, Rubin LJ, Magliola L, Jones AW. PMID: 15085060.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    201. Preoperative partitioning of pulmonary vascular resistance correlates with early outcome after thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Circulation. 2004 Jan 06; 109(1):18-22. Kim NH, Fesler P, Channick RN, Knowlton KU, Ben-Yehuda O, Lee SH, Naeije R, Rubin LJ. PMID: 14699009.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    202. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest. 2003 Oct; 124(4):1612-5. Kim NH, Channick RN, Rubin LJ. PMID: 14555600.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    203. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost. 2003 Sep; 90(3):372-6. Bonderman D, Turecek PL, Jakowitsch J, Weltermann A, Adlbrecht C, Schneider B, Kneussl M, Rubin LJ, Kyrle PA, Klepetko W, Maurer G, Lang IM. PMID: 12958604.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    204. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003 Jul; 124(1):247-54. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, Tapson VF, Rubin LJ. PMID: 12853530.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    205. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Jun 18; 41(12):2119-25. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R, Beraprost Study Group. PMID: 12821234.
      View in: PubMed   Mentions: 126     Fields:    Translation:HumansCTClinical Trials
    206. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2003 Sep; 285(3):L740-54. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, Thistlethwaite PA, Kriett JM, Yung G, Rubin LJ, Yuan JX. PMID: 12740218.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCells
    207. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Apr 16; 41(8):1380-6. Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, Espinola-Zavaleta N, Rocchi G, Manes A, Frantz R, Kurzyna M, Nagueh SF, Barst R, Channick R, Dujardin K, Kronenberg A, Leconte I, Rainisio M, Rubin L. PMID: 12706935.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    208. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003 Feb; 41(2):293-9. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S, Treprostinil Study Group. PMID: 12548091.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    209. Epoprostenol therapy as a bridge to pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Chest. 2003 Feb; 123(2):319-20. Kerr KM, Rubin LJ. PMID: 12576339.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    210. Single arterial occlusion to locate resistance in patients with pulmonary hypertension. Eur Respir J. 2003 Jan; 21(1):31-6. Fesler P, Pagnamenta A, Vachiéry JL, Brimioulle S, Abdel Kafi S, Boonstra A, Delcroix M, Channick RN, Rubin LJ, Naeije R. PMID: 12570105.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    211. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med. 2002 Nov 15; 166(10):1308-9. Rubin LJ. PMID: 12421739.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    212. Chronic thromboembolic pulmonary hypertension. Prog Cardiovasc Dis. 2002 Nov-Dec; 45(3):203-12. Williamson TL, Kim NH, Rubin LJ. PMID: 12525996.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    213. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 Aug 01; 347(5):322-9. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W, Aerosolized Iloprost Randomized Study Group. PMID: 12151469.
      View in: PubMed   Mentions: 376     Fields:    Translation:HumansCTClinical Trials
    214. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs. 2002 Jul; 11(7):991-1002. Rubin LJ, Roux S. PMID: 12084009.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
    215. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002 May 01; 165(9):1209-16. Hoeper MM, Galiè N, Simonneau G, Rubin LJ. PMID: 11991870.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    216. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21; 346(12):896-903. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. PMID: 11907289.
      View in: PubMed   Mentions: 577     Fields:    Translation:HumansCTClinical Trials
    217. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 Mar 15; 165(6):800-4. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ, Treprostinil Study Group. PMID: 11897647.
      View in: PubMed   Mentions: 328     Fields:    Translation:HumansCTClinical Trials
    218. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol. 2002 Feb; 26(2):194-201. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. PMID: 11804870.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    219. Nitric oxide induces apoptosis by activating K+ channels in pulmonary vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2002 Jan; 282(1):H184-93. Krick S, Platoshyn O, Sweeney M, McDaniel SS, Zhang S, Rubin LJ, Yuan JX. PMID: 11748062.
      View in: PubMed   Mentions: 21     Fields:    Translation:Animals
    220. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther. 2002 Jan; 7(1):9-19. Kim NH, Rubin LJ. PMID: 12000973.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    221. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001 Nov 15; 345(20):1465-72. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. PMID: 11794196.
      View in: PubMed   Mentions: 99     Fields:    Translation:Humans
    222. Increased levels of prostaglandin D(2) suggest macrophage activation in patients with primary pulmonary hypertension. Chest. 2001 Nov; 120(5):1639-44. Robbins IM, Barst RJ, Rubin LJ, Gaine SP, Price PV, Morrow JD, Christman BW. PMID: 11713147.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    223. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001 Oct 06; 358(9288):1119-23. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ. PMID: 11597664.
      View in: PubMed   Mentions: 309     Fields:    Translation:HumansCTClinical Trials
    224. Augmented K(+) currents and mitochondrial membrane depolarization in pulmonary artery myocyte apoptosis. Am J Physiol Lung Cell Mol Physiol. 2001 Oct; 281(4):L887-94. Krick S, Platoshyn O, McDaniel SS, Rubin LJ, Yuan JX. PMID: 11557592.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    225. Pulmonary vasoreactivity in PPH. J Am Coll Cardiol. 2001 Oct; 38(4):1267-8. Robbins IM, Barst RJ, Channick RN, Rubin LJ. PMID: 11587028.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    226. c-Jun decreases voltage-gated K(+) channel activity in pulmonary artery smooth muscle cells. Circulation. 2001 Sep 25; 104(13):1557-63. Yu Y, Platoshyn O, Zhang J, Krick S, Zhao Y, Rubin LJ, Rothman A, Yuan JX. PMID: 11571252.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    227. Chronic thromboembolic pulmonary hypertension. Clin Chest Med. 2001 Sep; 22(3):561-81. Fedullo PF, Auger WR, Channick RN, Kerr KM, Rubin LJ. PMID: 11590849.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    228. New and experimental therapies for pulmonary hypertension. Clin Chest Med. 2001 Sep; 22(3):539-45. Channick RN, Rubin LJ. PMID: 11590847.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    229. Inhibition of K(+) channel activity in human pulmonary artery smooth muscle cells by serum from patients with pulmonary hypertension secondary to congenital heart disease. Pediatr Res. 2001 Jul; 50(1):23-8. Limsuwan A, Platoshyn O, Yu Y, Rubin LJ, Rothman A, Yuan JX. PMID: 11420414.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    230. Characterization of an NBTI-sensitive equilibrative nucleoside transporter in vascular smooth muscle. J Mol Cell Cardiol. 2001 Jun; 33(6):1143-52. Dhalla AK, Dodam JR, Jones AW, Rubin LJ. PMID: 11444919.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    231. Therapy of pulmonary hypertension: targeting pathogenic mechanisms with selective treatment delivery. Crit Care Med. 2001 May; 29(5):1086-7. Rubin LJ. PMID: 11378627.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    232. Capacitative Ca(2+) entry in agonist-induced pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol. 2001 May; 280(5):L870-80. McDaniel SS, Platoshyn O, Wang J, Yu Y, Sweeney M, Krick S, Rubin LJ, Yuan JX. PMID: 11290510.
      View in: PubMed   Mentions: 48     Fields:    Translation:AnimalsCells
    233. Chronic hypoxia decreases K(V) channel expression and function in pulmonary artery myocytes. Am J Physiol Lung Cell Mol Physiol. 2001 Apr; 280(4):L801-12. Platoshyn O, Yu Y, Golovina VA, McDaniel SS, Krick S, Li L, Wang JY, Rubin LJ, Yuan JX. PMID: 11238022.
      View in: PubMed   Mentions: 60     Fields:    Translation:AnimalsCells
    234. A new era in the treatment of primary pulmonary hypertension. Heart. 2001 Mar; 85(3):251-2. Bailey CL, Channick RN, Rubin LJ. PMID: 11179256; PMCID: PMC1729642.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    235. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant. 2001 Feb; 20(2):262-263. Channick R, Badesch DB, Tapson VF, Simonneau G, Robbins I, Frost A, Roux S, Rainisio M, Bodin F, Rubin LJ. PMID: 11250530.
      View in: PubMed   Mentions: 23     Fields:    
    236. Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol. 2001 Feb; 280(2):H746-55. Golovina VA, Platoshyn O, Bailey CL, Wang J, Limsuwan A, Sweeney M, Rubin LJ, Yuan JX. PMID: 11158974.
      View in: PubMed   Mentions: 144     Fields:    Translation:HumansCells
    237. Approach to pulmonary hypertension. Curr Rheumatol Rep. 2000 Dec; 2(6):517-23. Yung GL, Rubin LJ. PMID: 11123107.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    238. Recreational use of aminorex and pulmonary hypertension. Chest. 2000 Nov; 118(5):1496-7. Gaine SP, Rubin LJ, Kmetzo JJ, Palevsky HI, Traill TA. PMID: 11083709.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    239. "High probability" perfusion lung scans in pulmonary venoocclusive disease. Am J Respir Crit Care Med. 2000 Nov; 162(5):1974-8. Bailey CL, Channick RN, Auger WR, Fedullo PF, Kerr KM, Yung GL, Rubin LJ. PMID: 11069842.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    240. Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am J Physiol Cell Physiol. 2000 Nov; 279(5):C1540-9. Platoshyn O, Golovina VA, Bailey CL, Limsuwan A, Krick S, Juhaszova M, Seiden JE, Rubin LJ, Yuan JX. PMID: 11029301.
      View in: PubMed   Mentions: 55     Fields:    Translation:AnimalsCells
    241. Selective transport of adenosine into porcine coronary smooth muscle. Am J Physiol Heart Circ Physiol. 2000 Sep; 279(3):H1397-410. Rubin LJ, Johnson LR, Dodam JR, Dhalla AK, Magliola L, Laughlin MH, Jones AW. PMID: 10993808.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    242. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000 Mar 21; 132(6):425-34. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jöbsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA. PMID: 10733441.
      View in: PubMed   Mentions: 203     Fields:    Translation:HumansCTClinical Trials
    243. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest. 2000 Mar; 117(3):870-4. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. PMID: 10713017.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansPHPublic Health
    244. The natural history of acute and chronic thromboembolic disease: the search for the missing link. Eur Respir J. 2000 Mar; 15(3):435-7. Fedullo PF, Rubin LJ, Kerr KM, Auger WR, Channick RN. PMID: 10759432.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    245. Combination therapy for pulmonary hypertension: a glimpse into the future? Crit Care Med. 2000 Mar; 28(3):896-7. Channick RN, Rubin LJ. PMID: 10752856.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    246. Mortality from primary pulmonary hypertension in the United States, 1979-1996. Chest. 2000 Mar; 117(3):796-800. Lilienfeld DE, Rubin LJ. PMID: 10713009.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    247. Laminectomy versus percutaneous electrode placement for spinal cord stimulation. Neurosurgery. 2000 Feb; 46(2):399-405; discussion 405-6. Villavicencio AT, Leveque JC, Rubin L, Bulsara K, Gorecki JP. PMID: 10690729.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    248. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest. 2000 Jan; 117(1):14-8. Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin LJ, Loyd JE. PMID: 10631192.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    249. Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease. Chest. 1999 Oct; 116(4):1127-9. Bakst AE, Gaine SP, Rubin LJ. PMID: 10531185.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    250. Endothelin-1 sensitivity of porcine coronary arteries is reduced by exercise training and is gender dependent. J Appl Physiol (1985). 1999 Sep; 87(3):1172-7. Jones AW, Rubin LJ, Magliola L. PMID: 10484592.
      View in: PubMed   Mentions: 10     Fields:    Translation:Animals
    251. Anastomotic pulmonary hypertension after lung transplantation for primary pulmonary hypertension: report of surgical correction. Chest. 1999 Aug; 116(2):564-6. Soriano CM, Gaine SP, Conte JV, Fairman RP, White C, Rubin LJ. PMID: 10453890.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    252. Portopulmonary hypertension and the liver transplant candidate. Transplantation. 1999 Apr 27; 67(8):1087-93. Kuo PC, Plotkin JS, Gaine S, Schroeder RA, Rustgi VK, Rubin LJ, Johnson LB. PMID: 10232556.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    253. Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. Pediatr Pulmonol Suppl. 1999; 18:194-7. Rubin LJ. PMID: 10093141.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    254. Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA). Cell Mol Biol (Noisy-le-grand). 1998 Nov; 44(7):1129-38. Newkirk MM, LePage K, Niwa T, Rubin L. PMID: 9846895.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    255. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation. 1998 Oct 06; 98(14):1400-6. Yuan JX, Aldinger AM, Juhaszova M, Wang J, Conte JV, Gaine SP, Orens JB, Rubin LJ. PMID: 9760294.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCells
    256. Short-term outcome and predictors of adverse events following pulmonary thromboendarterectomy. World J Surg. 1998 Oct; 22(10):1029-32; discussion 1033. Gilbert TB, Gaine SP, Rubin LJ, Sequeira AJ. PMID: 9747161.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    257. Primary pulmonary hypertension. Lancet. 1998 Aug 29; 352(9129):719-25. Gaine SP, Rubin LJ. PMID: 9729004.
      View in: PubMed   Mentions: 115     Fields:    Translation:Humans
    258. Action of fenfluramine on voltage-gated K+ channels in human pulmonary-artery smooth-muscle cells. Lancet. 1998 Jul 25; 352(9124):290. Wang J, Juhaszova M, Conte JV, Gaine SP, Rubin LJ, Yuan JX. PMID: 9690417.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    259. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. J Heart Lung Transplant. 1998 Jul; 17(7):679-85. Conte JV, Gaine SP, Orens JB, Harris T, Rubin LJ. PMID: 9703232.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    260. Purification of a multipotent antideath activity from bovine liver and its identification as arginase: nitric oxide-independent inhibition of neuronal apoptosis. J Neurosci. 1998 Jun 01; 18(11):4083-95. Esch F, Lin KI, Hills A, Zaman K, Baraban JM, Chatterjee S, Rubin L, Ash DE, Ratan RR. PMID: 9592089; PMCID: PMC6792820.
      View in: PubMed   Mentions: 23     Fields:    Translation:AnimalsCells
    261. The pulmonary circulation: snapshots of progress. Am J Respir Crit Care Med. 1998 Apr; 157(4 Pt 2):S101-8. Reeves JT, Rubin LJ. PMID: 9563768.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    262. Molecular basis and function of voltage-gated K+ channels in pulmonary arterial smooth muscle cells. Am J Physiol. 1998 04; 274(4):L621-35. Yuan XJ, Wang J, Juhaszova M, Golovina VA, Rubin LJ. PMID: 9575881.
      View in: PubMed   Mentions: 38     Fields:    Translation:AnimalsCells
    263. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet. 1998 Mar 07; 351(9104):726-7. Yuan XJ, Wang J, Juhaszova M, Gaine SP, Rubin LJ. PMID: 9504523.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCells
    264. Medical and surgical treatment options for pulmonary hypertension. Am J Med Sci. 1998 Mar; 315(3):179-84. Gaine SP, Rubin LJ. PMID: 9519930.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    265. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation. 1998 Feb 27; 65(4):457-9. Plotkin JS, Kuo PC, Rubin LJ, Gaine S, Howell CD, Laurin J, Njoku MJ, Lim JW, Johnson LB. PMID: 9500616.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    266. Roles of K+ and Cl- channels in cAMP-induced pulmonary vasodilation. Exp Lung Res. 1998 Jan-Feb; 24(1):71-83. Zhao YJ, Wang J, Rubin LJ, Yuan XJ. PMID: 9457470.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    267. Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells. J Clin Invest. 1997 Nov 01; 100(9):2347-53. Wang J, Juhaszova M, Rubin LJ, Yuan XJ. PMID: 9410914; PMCID: PMC508432.
      View in: PubMed   Mentions: 71     Fields:    Translation:AnimalsCells
    268. Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs. Am J Physiol. 1997 11; 273(5):H2312-24. Zhong J, Hwang TC, Adams HR, Rubin LJ. PMID: 9374768.
      View in: PubMed   Mentions: 34     Fields:    Translation:AnimalsCells
    269. Distinctive clinical features of portopulmonary hypertension. Chest. 1997 Oct; 112(4):980-6. Kuo PC, Plotkin JS, Johnson LB, Howell CD, Laurin JM, Bartlett ST, Rubin LJ. PMID: 9377962.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    270. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. JAMA. 1997 Aug 27; 278(8):666-72. McCann UD, Seiden LS, Rubin LJ, Ricaurte GA. PMID: 9272900.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    271. Cytosolic Ca2+ concentration and contraction-relaxation properties of ventricular myocytes from Escherichia coli endotoxemic guinea pigs: effect of fluid resuscitation. Shock. 1997 May; 7(5):383-8. Zhong J, Adams HR, Rubin LJ. PMID: 9165675.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    272. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation. 1997 Mar 18; 95(6):1479-86. Hinderliter AL, Willis PW, Barst RJ, Rich S, Rubin LJ, Badesch DB, Groves BM, McGoon MD, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Koch G, Li S, Clayton LM, Jöbsis MM, Blackburn SD, Crow JW, Long WA. PMID: 9118516.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    273. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation. 1997 Feb 27; 63(4):604-6. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. PMID: 9047158.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    274. Inhibition of K(V) and K(Ca) channels antagonizes NO-induced relaxation in pulmonary artery. Am J Physiol. 1997 Feb; 272(2 Pt 2):H904-12. Zhao YJ, Wang J, Rubin LJ, Yuan XJ. PMID: 9124454.
      View in: PubMed   Mentions: 17     Fields:    Translation:Animals
    275. Primary pulmonary hypertension. N Engl J Med. 1997 Jan 09; 336(2):111-7. Rubin LJ. PMID: 8988890.
      View in: PubMed   Mentions: 264     Fields:    Translation:Humans
    276. Nitric oxide inhibits serotonin-induced calcium release in pulmonary artery smooth muscle cells. Am J Physiol. 1997 Jan; 272(1 Pt 1):L44-50. Yuan XJ, Bright RT, Aldinger AM, Rubin LJ. PMID: 9038901.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    277. [3H]benzylpempidine, a new radioligand for probing a putative channel site on nicotinic cholinergic receptors. Life Sci. 1997; 60(15):1271-7. Wang DX, Sheu SS, Sharma VK, Rubin L, Journet M, Kende AS, Abood LG. PMID: 9096244.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    278. Pulmonary vasoconstrictor effects of prostacyclin in rats: potential role of thromboxane receptors. J Appl Physiol (1985). 1996 Dec; 81(6):2595-603. Zhao YJ, Wang J, Tod ML, Rubin LJ, Yuan XJ. PMID: 9018511.
      View in: PubMed   Mentions: 8     Fields:    Translation:Animals
    279. Minimizing graft rejection in allogeneic T cell-depleted bone marrow transplantation. Bone Marrow Transplant. 1996 Nov; 18(5):913-9. Rigden JP, Cornetta K, Srour EF, Hanna M, Broun ER, Hromas R, Baute J, Hilton J, Cox E, Rubin L, Gonin R, Tricot G. PMID: 8932845.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    280. NO hyperpolarizes pulmonary artery smooth muscle cells and decreases the intracellular Ca2+ concentration by activating voltage-gated K+ channels. Proc Natl Acad Sci U S A. 1996 Sep 17; 93(19):10489-94. Yuan XJ, Tod ML, Rubin LJ, Blaustein MP. PMID: 8816828; PMCID: PMC38412.
      View in: PubMed   Mentions: 36     Fields:    Translation:AnimalsCells
    281. The renin-angiotensin system and the "lesser circulation". A role in cor pulmonale? Chest. 1996 Sep; 110(3):584-5. Rubin LJ. PMID: 8797391.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    282. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 01; 334(5):296-301. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW, Primary Pulmonary Hypertension Study Group. PMID: 8532025.
      View in: PubMed   Mentions: 558     Fields:    Translation:HumansCTClinical Trials
    283. A mitochondrial uncoupler increases KCa currents but decreases KV currents in pulmonary artery myocytes. Am J Physiol. 1996 Jan; 270(1 Pt 1):C321-31. Yuan XJ, Sugiyama T, Goldman WF, Rubin LJ, Blaustein MP. PMID: 8772460.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    284. Endotoxin-induced myocardial dysfunction: is there a role for nitric oxide? Shock. 1995 Nov; 4(5):338-44. Keller RS, Jones JJ, Kim KF, Myers PR, Adams HR, Parker JL, Rubin LJ. PMID: 8595520.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    285. Hypoxic and metabolic regulation of voltage-gated K+ channels in rat pulmonary artery smooth muscle cells. Exp Physiol. 1995 Sep; 80(5):803-13. Yuan XJ, Tod ML, Rubin LJ, Blaustein MP. PMID: 8546869.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    286. Inhibition of glycolysis by 2-DG increases [Ca2+]i in pulmonary arterial smooth muscle cells. Am J Physiol. 1995 Aug; 269(2 Pt 1):L203-8. Bright RT, Salvaterra CG, Rubin LJ, Yuan XJ. PMID: 7653581.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    287. Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol. 1995 Jan 19; 75(3):51A-54A. Rubin LJ. PMID: 7840055.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    288. Inhibition of cytochrome P-450 reduces voltage-gated K+ currents in pulmonary arterial myocytes. Am J Physiol. 1995 Jan; 268(1 Pt 1):C259-70. Yuan XJ, Tod ML, Rubin LJ, Blaustein MP. PMID: 7840155.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    289. The Duke experience with nucleus caudalis DREZ coagulation. Stereotact Funct Neurosurg. 1995; 65(1-4):111-6. Gorecki JP, Nashold BS, Rubin L, Ovelmen-Levitt J. PMID: 8916338.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    290. Escherichia coli endotoxin inhibits agonist-mediated cytosolic Ca2+ mobilization and nitric oxide biosynthesis in cultured endothelial cells. Circ Res. 1994 Oct; 75(4):659-68. Graier WF, Myers PR, Rubin LJ, Adams HR, Parker JL. PMID: 7923612.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    291. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994 Sep 15; 121(6):409-15. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. PMID: 8053614.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCTClinical Trials
    292. Cardiodynamic response to Escherichia coli endotoxemia: effects of fluid resuscitation. Shock. 1994 Sep; 2(3):203-9. Zhong J, Rubin LJ, Parker JL, Adams HR. PMID: 7743351.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    293. Deoxyglucose and reduced glutathione mimic effects of hypoxia on K+ and Ca2+ conductances in pulmonary artery cells. Am J Physiol. 1994 Jul; 267(1 Pt 1):L52-63. Yuan XJ, Tod ML, Rubin LJ, Blaustein MP. PMID: 8048542.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    294. Investigation and management of pulmonary hypertension in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993 Nov; 148(5):1414-7. Salvaterra CG, Rubin LJ. PMID: 8239185.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    295. Primary pulmonary hypertension. Chest. 1993 Jul; 104(1):236-50. Rubin LJ. PMID: 8325077.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    296. Nitrone spin-traps block calcium channels and induce pulmonary artery relaxation independent of free radicals. Biochem Biophys Res Commun. 1993 Jun 30; 193(3):878-85. Anderson DE, Yuan XJ, Tseng CM, Rubin LJ, Rosen GM, Tod ML. PMID: 8391809.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    297. Hypoxia reduces potassium currents in cultured rat pulmonary but not mesenteric arterial myocytes. Am J Physiol. 1993 Feb; 264(2 Pt 1):L116-23. Yuan XJ, Goldman WF, Tod ML, Rubin LJ, Blaustein MP. PMID: 8447425.
      View in: PubMed   Mentions: 71     Fields:    Translation:AnimalsCells
    298. Ionic currents in rat pulmonary and mesenteric arterial myocytes in primary culture and subculture. Am J Physiol. 1993 Feb; 264(2 Pt 1):L107-15. Yuan XJ, Goldman WF, Tod ML, Rubin LJ, Blaustein MP. PMID: 8447424.
      View in: PubMed   Mentions: 26     Fields:    Translation:AnimalsCells
    299. NG-monomethyl-L-arginine paradoxically relaxes preconstricted canine intrapulmonary arteries. J Appl Physiol (1985). 1993 Feb; 74(2):549-58. Tseng CM, Goodman LW, Rubin LJ, Tod ML. PMID: 8458770.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    300. Pulmonary vascular responses to thromboxane and prostacyclin. J Appl Physiol (1985). 1992 Dec; 73(6):2717-9. Tod ML, Rubin LJ. PMID: 1490991.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    301. Lymphadenopathy, oligoclonal T cell receptor rearrangement and systemic lupus erythematosus. J Rheumatol. 1992 Dec; 19(12):1966-9. Khraishi M, Reis M, Berinstein N, Rubin L. PMID: 1294749.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    302. Ontogeny of neonatal pulmonary vascular pressure-flow relationships. Am J Physiol. 1992 Mar; 262(3 Pt 2):H684-90. Tod ML, Yoshimura K, Rubin LJ. PMID: 1558176.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    303. Primary pulmonary hypertension. Practical therapeutic recommendations. Drugs. 1992 Jan; 43(1):37-43. Rubin LJ. PMID: 1372858.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    304. Comparison of titanium-mesh and porous disc electrodes for epicardial defibrillation. Pacing Clin Electrophysiol. 1991 Nov; 14(11 Pt 2):1860-4. Rubin L, Rosenberg D, Parsonnet V, Villaneuva A, Ferrara-Ryan M. PMID: 1721189.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    305. Reversible pulmonary hypertension associated with anorexigen use. Am J Med. 1991 Jul; 91(1):97-9. Nall KC, Rubin LJ, Lipskind S, Sennesh JD. PMID: 1858837.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    306. Indomethacin prevents ventilation-induced decreases in pulmonary vascular resistance of the middle region in fetal lambs. Pediatr Res. 1991 May; 29(5):449-54. Tod ML, Yoshimura K, Rubin LJ. PMID: 1910157.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    307. New concepts in the treatment of primary pulmonary hypertension. Md Med J. 1991 Mar; 40(3):209-11. Rubin LJ. PMID: 2008166.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    308. Pulmonary vascular distensibility of arterial, middle, and venous regions in newborn lambs. J Appl Physiol (1985). 1991 Mar; 70(3):1315-22. Tod ML, Yoshimura K, Rubin LJ. PMID: 2032998.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    309. Cardiovascular effects of pulmonary hypertension. Trends Cardiovasc Med. 1991 Mar; 1(2):65-9. Salvaterra CG, Rubin LJ. PMID: 21239332.
      View in: PubMed   Mentions:    Fields:    
    310. Effects of nitrendipine and hypoxia on pulmonary vascular resistance in experimental emphysema. Am Rev Respir Dis. 1990 Sep; 142(3):625-30. Rubin LJ, Tod ML, Yoshimura K. PMID: 2389915.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    311. Contrasting effects of hypoxia on tension in rat pulmonary and mesenteric arteries. Am J Physiol. 1990 Aug; 259(2 Pt 2):H281-9. Yuan XJ, Tod ML, Rubin LJ, Blaustein MP. PMID: 2117400.
      View in: PubMed   Mentions: 29     Fields:    Translation:Animals
    312. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990 Apr 01; 112(7):485-91. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W. PMID: 2107780.
      View in: PubMed   Mentions: 151     Fields:    Translation:HumansCTClinical Trials
    313. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis. 1989 Dec; 140(6):1623-30. Weir EK, Rubin LJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Elliott CG, Fishman AP, Goldring RM, Groves BM, et al. PMID: 2690706.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    314. Effects of a thromboxane A2 analogue and prostacyclin on lung fluid balance in newborn lambs. Circ Res. 1989 Nov; 65(5):1409-16. Yoshimura K, Tod ML, Pier KG, Rubin LJ. PMID: 2509097.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    315. Approach to the diagnosis and treatment of pulmonary hypertension. Chest. 1989 Sep; 96(3):659-64. Rubin LJ. PMID: 2766828.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    316. Cloning of a cDNA encoding the rat high molecular weight neurofilament peptide (NF-H): developmental and tissue expression in the rat, and mapping of its human homologue to chromosomes 1 and 22. Proc Natl Acad Sci U S A. 1989 Apr; 86(7):2463-7. Lieberburg I, Spinner N, Snyder S, Anderson J, Goldgaber D, Smulowitz M, Carroll Z, Emanuel B, Breitner J, Rubin L. PMID: 2928342; PMCID: PMC286933.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    317. The influence of the transmembrane sodium gradient on the responses of pulmonary arteries to decreases in oxygen tension. Am Rev Respir Dis. 1989 Apr; 139(4):933-9. Salvaterra CG, Rubin LJ, Schaeffer J, Blaustein MP. PMID: 2539035.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    318. Role of venoconstriction in thromboxane-induced pulmonary hypertension and edema in lambs. J Appl Physiol (1985). 1989 Feb; 66(2):929-35. Yoshimura K, Tod ML, Pier KG, Rubin LJ. PMID: 2651387.
      View in: PubMed   Mentions: 8     Fields:    Translation:Animals
    319. Effects of interleukin-2 on oxygen delivery and consumption in patients with advanced malignancy. Chest. 1988 Oct; 94(4):816-21. Silverman HJ, Abrams J, Rubin LJ. PMID: 3262489.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    320. Primary pulmonary hypertension. Chest. 1988 Apr; 93(4):894-5. Rubin LJ. PMID: 3280265.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    321. Pulmonary vascular structural and functional changes in papain-induced emphysema in dogs. Am Rev Respir Dis. 1987 Sep; 136(3):704-9. Rubin LJ, Windberg P, Taylor W, Heatfield B. PMID: 3631741.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    322. Prostacyclin and PGE1 treatment of pulmonary hypertension. Am Rev Respir Dis. 1987 Sep; 136(3):773-6. Long WA, Rubin LJ. PMID: 3307575.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    323. Noninvasive evaluation of right ventricular function. Clin Chest Med. 1987 Mar; 8(1):65-80. Johnson RA, Rubin LJ. PMID: 3552388.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    324. Vasodilators and pulmonary hypertension: where do we go from here? Am Rev Respir Dis. 1987 Feb; 135(2):287. Rubin LJ. PMID: 3813188.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    325. Characteristics of sheltered homeless families. Am J Public Health. 1986 Sep; 76(9):1097-101. Bassuk EL, Rubin L, Lauriat AS. PMID: 3740332; PMCID: PMC1646563.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    326. Therapy of secondary pulmonary hypertension. Heart Lung. 1986 Sep; 15(5):450-6. Peil ML, Rubin LJ. PMID: 3639073.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    327. The effects of hydralazine on exercise capacity in pulmonary hypertension secondary to chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986 Mar; 133(3):385-9. Dal Nogare AR, Rubin LJ. PMID: 3954247.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    328. Oxygen therapy titrated to raise mixed venous oxygen content in COPD. Chest. 1986 Mar; 89(3):343-7. Peil ML, Rubin LJ. PMID: 3948546.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    329. Primary pulmonary hypertension. An analysis of 28 cases and a review of the literature. Medicine (Baltimore). 1986 Jan; 65(1):56-72. Hughes JD, Rubin LJ. PMID: 2867454.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    330. Long-term effects of nitrendipine on hemodynamics and oxygen transport in patients with cor pulmonale. Chest. 1986 Jan; 89(1):141-5. Rubin LJ, Moser K. PMID: 2934230.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    331. A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension. Am Heart J. 1985 Dec; 110(6):1200-4. Groves BM, Rubin LJ, Frosolono MF, Cato AE, Reeves JT. PMID: 3907315.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    332. Calcium channel blockers in primary pulmonary hypertension. Chest. 1985 Oct; 88(4 Suppl):257S-260S. Rubin LJ. PMID: 4042732.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    333. Pulmonary thromboembolic disease--diagnosis, management and prevention. Am J Med Sci. 1985 Oct; 290(4):167-77. Rubin LJ. PMID: 4073115.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    334. The effects of eicosanoid synthesis inhibitors on normoxic and hypoxic pulmonary vascular tone in dogs. Am Rev Respir Dis. 1985 Jul; 132(1):93-8. Rubin LJ, Hughes JD, Lazar JD. PMID: 3925829.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    335. Nafazatrom (Bay g 6575) blunts canine hypoxic pulmonary vasoconstriction: evidence for a prostaglandin-mediated mechanism. Prostaglandins Leukot Med. 1985 Apr; 18(1):95-104. Ensley RD, Rubin LJ. PMID: 3923499.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    336. Is homelessness a mental health problem? Am J Psychiatry. 1984 Dec; 141(12):1546-50. Bassuk EL, Rubin L, Lauriat A. PMID: 6209990.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    337. Relation between mixed venous oxygen tension and pulmonary vascular tone during normoxic, hyperoxic and hypoxic ventilation in dogs. Am J Cardiol. 1984 Nov 01; 54(8):1118-23. Hughes JD, Rubin LJ. PMID: 6496333.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    338. Systemic lupus erythematosus with paraproteinemia. Arthritis Rheum. 1984 Jun; 27(6):638-44. Rubin L, Urowitz MB, Pruzanski W. PMID: 6610425.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    339. Modulation of the response of a photosensitive muscle by beta-adrenergic regulation of cyclic AMP levels. Nature. 1984 Feb 9-15; 307(5951):551-3. Rubin LJ, Nolte JF. PMID: 6141528.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    340. Effects of oral hydralazine on gas exchange in patients with cor pulmonale. Am J Med. 1983 Dec; 75(6):937-42. Miller MJ, Chappell TR, Cook W, De Olazabal JR, Rubin LJ. PMID: 6650548.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    341. Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation. Ann Intern Med. 1983 Oct; 99(4):433-8. Rubin LJ, Nicod P, Hillis LD, Firth BG. PMID: 6625374.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    342. High sodium bicarbonate and acetate hemodialysis: double-blind crossover comparison of hemodynamic and ventilatory effects. Kidney Int. 1983 Aug; 24(2):240-5. Henrich WL, Woodard TD, Meyer BD, Chappell TR, Rubin LJ. PMID: 6314029.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    343. Independence of oxygen consumption and systemic oxygen transport in patients with either stable pulmonary hypertension or refractory left ventricular failure. Am Rev Respir Dis. 1983 Jul; 128(1):30-3. Chappell TR, Rubin LJ, Markham RV, Firth BG. PMID: 6870066.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    344. Primary pulmonary hypertension: an unusual case associated with extrahepatic portal hypertension. Hepatology. 1983 Jul-Aug; 3(4):588-92. Cohen MD, Rubin LJ, Taylor WE, Cuthbert JA. PMID: 6862372.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    345. Nonadrenergic effects of isoproterenol in dogs with hypoxic pulmonary vasoconstriction. Possible role of prostaglandins. J Clin Invest. 1983 May; 71(5):1366-74. Rubin LJ, Lazar JD. PMID: 6406548; PMCID: PMC437000.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    346. Cardiovascular effects of vasodilator therapy for pulmonary arterial hypertension. Clin Chest Med. 1983 May; 4(2):309-19. Rubin LJ. PMID: 6342925.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    347. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982 Aug; 66(2):334-8. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. PMID: 7046988.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    348. The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure. Circulation. 1982 Jun; 65(7):1369-73. Rubin LJ, Handel F, Peter RH. PMID: 7074795.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    349. Hemodynamics at rest and during exercise after oral hydralazine in patients with cor pulmonale. Am J Cardiol. 1981 Jan; 47(1):116-22. Rubin LJ, Peter RH. PMID: 7457397.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    350. Influence of prostaglandin synthesis inhibitors on pulmonary vasodilatory effects of hydralazine in dogs with hypoxic pulmonary vasoconstriction. J Clin Invest. 1981 Jan; 67(1):193-200. Rubin LJ, Lazar JD. PMID: 7451649; PMCID: PMC371587.
      View in: PubMed   Mentions: 9     Fields:    Translation:Animals
    351. Primary pulmonary hypertension: new approaches to therapy. Am Heart J. 1980 Nov; 100(5):757-9. Rubin LJ, Peter RH. PMID: 7446372.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    352. Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med. 1980 Jan 10; 302(2):69-73. Rubin LJ, Peter RH. PMID: 7350435.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    353. Letter: Nurse practitioners. Ann Intern Med. 1975 Aug; 83(2):278-9. Rubin LJ, Katz RS. PMID: 1147467.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Lewis's Networks
    Concepts (854)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (24)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-4-g3cb31450 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California